June 18, 2020: Existing evidence-based interventions aren't enough to close HIV's racial gap; transgender patient outcomes in the HIV care continuum; meeting long-term needs of formerly incarcerated people; acute respiratory illness severity and HIV status.
Kaiser Permanente’s 2-1-1 pre-exposure prophylaxis (PrEP) program shows event-driven dosing works.
June 11, 2020: Diagnosis rates within a year of infection; rates of intentional non-daily PrEP use; neurological development in children of birth parents with HIV; point-of-care urine test to assess tenofovir levels.
Investigational PrEP Injection, Dosed Every Other Month, Holds Up Against Daily PrEP in Phase 3 Study
The long-acting injectable drug cabotegravir proved non-inferior to daily oral TDF/FTC for MSM and transgender women.
Increased HIV Testing and Treatment for Black Bisexual Men May Have Played a Role in HIV Drop in Black Women. But Has the Stigma Gone Away?
Researchers say the “bisexual bridge” theory creates stigma and biphobia.
COVID-19 Impacts Gay and Bisexual Men's Mental Health, Sexual Behavior, and Access to HIV/STI Services
This new study is the first to look at the impacts of the coronavirus pandemic on men who have sex with men.
May 7, 2020: Epidemiological factors among transgender women; revised PrEP indication estimates for MSM; trends in HIV strain similarity between younger and older MSM; current hepatitis C epidemic among British MSM with HIV.
April 9, 2020: Rapid efficacy of integrase-based treatment; a potent PrEP ad campaign in Chicago; more frequent STI screening for PrEP users; Ryan White funding fuels critical rural HIV care and services.
With Truvada going generic soon in the U.S., public health officials will need to make some decisions to make access to both drugs sustainable.
Feb. 27, 2020: U=U perception vs. reality; frequency of incorrect self-reported viral load levels; how HIV transmission cluster predicts care continuum gaps; integrase inhibitor uptake and discontinuation.